Tirzepatide in the UAE: what every patient should know before starting
A plain English guide to tirzepatide in the Emirates: eligibility, dosing, side effects, and what good doctor follow up actually looks like.
Tirzepatide is a dual GLP-1 / GIP agonist and a clinically supported injectable weight loss therapy available in the UAE. At Orvion, every patient who starts on tirzepatide does so after a structured online consultation with a UAE licensed physician. Here is what we tell every patient before they start.
How it works
Tirzepatide activates two gut hormone receptors at once. The result is reduced appetite, slower gastric emptying, and improved insulin sensitivity. In clinical trials it produced average weight loss of 15 to 22 percent over 72 weeks at the highest dose.
Who is eligible
- Adults with a BMI of 30+, or 27+ with a weight related condition such as type 2 diabetes, hypertension or sleep apnea.
- No personal or family history of medullary thyroid carcinoma or MEN2.
- Not pregnant, breastfeeding, or actively trying to conceive.
What the first month looks like
Most patients start at 2.5mg weekly for four weeks before titrating up. Common first month side effects (nausea, fatigue, mild constipation) usually settle as the body adapts. Your Orvion doctor checks in twice in the first month and adjusts dose if needed.
Weight loss medication is not a shortcut. It is a tool that works best paired with the right protein intake, strength training, and sleep, plus a doctor who actually picks up the phone.
What good follow up looks like
At minimum: a check in at week 2, week 4, and monthly thereafter. If your provider is not following up at this cadence, you are not getting weight loss care. You are getting a prescription. Orvion's standard is unlimited follow up messaging with your physician at no extra cost.
